181 related articles for article (PubMed ID: 20014166)
1. Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006.
Katz N; Panas L; Kim M; Audet AD; Bilansky A; Eadie J; Kreiner P; Paillard FC; Thomas C; Carrow G
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):115-23. PubMed ID: 20014166
[TBL] [Abstract][Full Text] [Related]
2. The influence of prescription monitoring programs on chronic pain management.
Wang J; Christo PJ
Pain Physician; 2009; 12(3):507-15. PubMed ID: 19461820
[TBL] [Abstract][Full Text] [Related]
3. Do prescription monitoring programs impact state trends in opioid abuse/misuse?
Reifler LM; Droz D; Bailey JE; Schnoll SH; Fant R; Dart RC; Bucher Bartelson B
Pain Med; 2012 Mar; 13(3):434-42. PubMed ID: 22299725
[TBL] [Abstract][Full Text] [Related]
4. Prescriptions for schedule II opioids and benzodiazepines increase after the introduction of computer-generated prescriptions.
McGerald G; Dvorkin R; Levy D; Lovell-Rose S; Sharma A
Acad Emerg Med; 2009 Jun; 16(6):508-12. PubMed ID: 19388914
[TBL] [Abstract][Full Text] [Related]
5. Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group.
Young LD; Kreiner PW; Panas L
Pain Med; 2018 Jul; 19(7):1396-1407. PubMed ID: 28383713
[TBL] [Abstract][Full Text] [Related]
6. Analytic models to identify patients at risk for prescription opioid abuse.
White AG; Birnbaum HG; Schiller M; Tang J; Katz NP
Am J Manag Care; 2009 Dec; 15(12):897-906. PubMed ID: 20001171
[TBL] [Abstract][Full Text] [Related]
7. National drug control policy and prescription drug abuse: facts and fallacies.
Manchikanti L
Pain Physician; 2007 May; 10(3):399-424. PubMed ID: 17525776
[TBL] [Abstract][Full Text] [Related]
8. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010.
Fischer B; Jones W; Krahn M; Rehm J
Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1269-77. PubMed ID: 21755568
[TBL] [Abstract][Full Text] [Related]
9. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Prescription Monitoring Programs in Reducing Opioid Prescribing, Dispensing, and Use Outcomes: A Systematic Review.
Wilson MN; Hayden JA; Rhodes E; Robinson A; Asbridge M
J Pain; 2019 Dec; 20(12):1383-1393. PubMed ID: 31059823
[TBL] [Abstract][Full Text] [Related]
11. Screening for potential prescription opioid misuse in a michigan medicaid population.
Braker LS; Reese AE; Card RO; Van Howe RS
Fam Med; 2009; 41(10):729-34. PubMed ID: 19882397
[TBL] [Abstract][Full Text] [Related]
12. Gender and non-medical use of prescription opioids: results from a national US survey.
Tetrault JM; Desai RA; Becker WC; Fiellin DA; Concato J; Sullivan LE
Addiction; 2008 Feb; 103(2):258-68. PubMed ID: 18042194
[TBL] [Abstract][Full Text] [Related]
13. Distance traveled and frequency of interstate opioid dispensing in opioid shoppers and nonshoppers.
Cepeda MS; Fife D; Yuan Y; Mastrogiovanni G
J Pain; 2013 Oct; 14(10):1158-61. PubMed ID: 23791042
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of prescribers whose patients shop for opioids: results from a cohort study.
Cepeda MS; Fife D; Berlin JA; Mastrogiovanni G; Yuan Y
J Opioid Manag; 2012; 8(5):285-91. PubMed ID: 23247905
[TBL] [Abstract][Full Text] [Related]
15. Opioid shopping behavior: how often, how soon, which drugs, and what payment method.
Cepeda MS; Fife D; Chow W; Mastrogiovanni G; Henderson SC
J Clin Pharmacol; 2013 Jan; 53(1):112-7. PubMed ID: 23400751
[TBL] [Abstract][Full Text] [Related]
16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
17. Effect of a triplicate prescription law on prescribing of Schedule II drugs.
Sigler KA; Guernsey BG; Ingrim NB; Buesing AS; Hokanson JA; Galvan E; Doutré WH
Am J Hosp Pharm; 1984 Jan; 41(1):108-11. PubMed ID: 6695926
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
Manchikanti L; Singh A
Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
[TBL] [Abstract][Full Text] [Related]
19. How does use of a prescription monitoring program change medical practice?
Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
Pain Med; 2012 Oct; 13(10):1314-23. PubMed ID: 22845339
[TBL] [Abstract][Full Text] [Related]
20. Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes.
Gilson AM; Fishman SM; Wilsey BL; Casamalhuapa C; Baxi H
J Pain; 2012 Feb; 13(2):103-11. PubMed ID: 22112420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
